{"brief_title": "Etanercept (Enbrel\u00ae) in Psoriasis - Pediatrics", "brief_summary": "This study will evaluate the safety and efficacy of etanercept (Enbrel\u00ae) in children with Psoriasis. This is a Phase 3 blinded, placebo-controlled study.", "condition": ["Psoriasis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Enbrel\u00ae", "Placebo"], "description": ["0.8 mg/kg (up to an intended dose of 50 mg) once weekly", "0.8 mg/kg (up to an intended dose of 50 mg) once weekly"], "arm_group_label": ["Enbrel", "Placebo"], "criteria": "- Patients with plaque psoriasis - Patient may not receive certain psoriasis medications during the study", "gender": "All", "minimum_age": "4 Years", "maximum_age": "17 Years", "healthy_volunteers": "No", "keyword": "Pediatric Psoriasis", "mesh_term": ["Psoriasis", "Etanercept"], "id": "NCT00078819"}